| Title: | Lack of genetic evidence for NLRP3 inflammasome involvement in Parkinson's disease pathogenesis |
| Journal: | npj Parkinson's Disease |
| Published: | 5 Aug 2024 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/39103393/ |
| DOI: | https://doi.org/10.1038/s41531-024-00744-9 |
Publication 12948
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Activation of the NLRP3 inflammasome has been implicated in Parkinson's disease (PD) based on in vitro and in vivo studies. Clinical trials targeting the NLRP3 inflammasome in PD are ongoing. However, the evidence supporting NLRP3's involvement in PD from human genetics data is limited. We analyzed common and rare variants in NLRP3 inflammasome-related genes in PD cohorts, performed pathway-specific polygenic risk score (PRS) analyses, and studied causal associations using Mendelian randomization (MR) with the NLRP3 components and the cytokines IL-1β and IL-18. Our findings showed no associations of common or rare variants, nor of the pathway PRS with PD. MR suggests that altering the expression of the NLRP3 inflammasome, IL-1β, or IL-18, does not affect PD risk or progression. Therefore, our results do not support a role for the NLRP3 inflammasome in PD pathogenesis or as a target for drug development.</p>
6 Authors
- Konstantin Senkevich
- Lang Liu
- Chelsea X. Alvarado
- Hampton L. Leonard
- Mike A. Nalls
- Ziv Gan-Or
1 Application
| Application ID | Title |
|---|---|
| 45551 | Mechanistic modelling of neurodevelopment, neuroplasticity, and neurodegeneration |
Enabling scientific discoveries that improve human health